ClearPoint Neuro, Inc.

CLPT

US18507C1036

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
5.51 ^USD	+3.38%		-1.78%	-18.85%

Apr. 16	ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia	MT
Mar. 13	Stifel Adjusts Price Target on ClearPoint Neuro to $9 From $8, Maintains Buy Rating	MT

ClearPoint Neuro, Inc.(NasdaqCM:CLPT) dropped from Russell Small Cap Comp Growth Index

June 24, 2022 at 12:00 am EDT

Latest news about ClearPoint Neuro, Inc.

ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia	Apr. 16	MT
Stifel Adjusts Price Target on ClearPoint Neuro to $9 From $8, Maintains Buy Rating	Mar. 13	MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Transcript : ClearPoint Neuro, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Earnings Flash (CLPT) CLEARPOINT NEURO Posts Q4 Revenue $6.8M, vs. Street Est of $6.5M	Mar. 12	MT
ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024	Mar. 12	CI
ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery	Mar. 11	CI
ClearPoint Neuro to Seek Acquisitions	Mar. 01	CI
ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model	Feb. 21	CI
ClearPoint Neuro, Inc. Announces Installation and First Procedure Using the Clearpoint Prism® Neuro Laser Therapy System and Navigation System At Kaleida Health in Buffalo	Jan. 24	CI
Clearpoint Neuro Receives 510(K) Clearance for Smartframe or Stereotactic System	Jan. 16	CI
ClearPoint Neuro Shares Up 16% After Prelim. 4Q Revenue Beats Estimates	Jan. 09	DJ
Clinical Laserthermia Systems Gets SEK8 Million Order from ClearPoint Neuro; Stocks Rise	Jan. 09	MT
ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year 2024	Jan. 08	CI
Lake Street Cuts ClearPoint Neuro Price Target to $11 From $15, Maintains Buy Rating	Nov. 10	MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : ClearPoint Neuro, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q3 Revenue $5.8M, vs. Street Est of $6.73M	Nov. 09	MT
ClearPoint Neuro, Inc. Provides Earnings Guidance for the Year 2023	Nov. 09	CI
Stifel Initiates ClearPoint Neuro With Buy Rating, Price Target is $8	23-10-24	MT
Lake Street Adjusts Price Target on ClearPoint Neuro to $15 From $22, Maintains Buy Rating	23-08-09	MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q2 Revenue $6M, vs. Street Est of $5.9M	23-08-08	MT
Transcript : ClearPoint Neuro, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
ClearPoint Neuro, Inc. Reaffirms Its Revenue Guidance for Full Year 2023	23-08-08	CI

ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Companyâs flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ClearPoint Neuro, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.51 USD

Average target price

10 USD

Spread / Average Target

+81.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CLEARPOINT NEURO, INC.	-18.85%	149M
THERMO FISHER SCIENTIFIC	+3.31%	209B
DANAHER CORPORATION	+2.05%	175B
INTUITIVE SURGICAL, INC.	+9.36%	131B
BOSTON SCIENTIFIC CORPORATION	+17.66%	99.98B
SIEMENS HEALTHINEERS AG	-2.17%	61.12B
EDWARDS LIFESCIENCES CORPORATION	+14.05%	52.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.15%	46.5B
AGILENT TECHNOLOGIES, INC.	-3.68%	39.24B
GE HEALTHCARE TECHNOLOGIES INC.	+9.04%	38.47B

Other Advanced Medical Equipment & Technology